Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.86 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.86 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.86 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.86 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.86 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.86 |
| ▸ | TSHR | P16473 | 1/20 | 0.86 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.86 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.86 |
| ▸ | DRD2 | P14416 | 15/20 | 0.80 |
| ▸ | DRD4 | P21917 | 15/20 | 0.80 |
| ▸ | HTR2A | P28223 | 1/20 | 0.68 |
| ▸ | NAMPT | P43490 | 1/20 | 0.67 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.67 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2900269 | 1.00 | TMEM97 (0.86) | TMEM97SIGMAR1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL3366478 | 0.93 | SIGMAR1 (1.00) | TMEM97SIGMAR1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7694199 | 0.91 | DRD2 (0.85) | TMEM97SIGMAR1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7694198 | 0.91 | DRD2 (0.85) | TMEM97SIGMAR1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL8707354 | 0.89 | DRD2 (1.00) | TMEM97SIGMAR1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL11555632 | 0.89 | DRD2 (0.82) | TMEM97SIGMAR1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL8706290 | 0.89 | DRD2 (1.00) | TMEM97SIGMAR1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL8706273 | 0.86 | DRD2 (0.89) | DRD2DRD4HTR2ANAMPT | |
| SCHEMBL8738231 | 0.86 | DRD2 (0.77) | DRD2DRD4HTR2AMCHR1 | |
| SCHEMBL8738579 | 0.86 | DRD2 (0.77) | DRD2DRD4HTR2AMCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816354-B2 | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2010-10-19 | — | — | US | disclosed |
| US-7816354-B2 | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2010-10-19 | — | — | US | disclosed |
| US-20090012089-A1 | Oxazolidinone Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | US | disclosed |
| US-20090012089-A1 | Oxazolidinone Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | US | disclosed |
| US-20070275966-A1 | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | NPS PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070275966-A1 | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | NPS PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| WO-2007078523-A2 | 5-PHENYL-3-BENZYL-0XAZ0LIDIN-2-0NE DERIVATIVES AND RELATED COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | ASTRAZENECA AB (SE) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275966-A1 | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | GRM1, GRIN1, GRM2 | TMEM97 265/4885SIGMAR1 175/4885CYP1A2 1932/4885 |
| US-20090012089-A1 | Oxazolidinone Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | GRM1, GRIN1, GRM2 | TMEM97 265/4885SIGMAR1 175/4885CYP1A2 1932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.